Νταπαγλιφλοζίνη (461432-26- 8)
Dapagliflozin is the first approved SGLT2 inhibitor for the treatment of type II diabetes, which is used to improve glycemic control as an adjunct to dietary and exercise for adults with type II diabetes. Product Name: Dapagliflozin CAS No.: 461432-26-8 Assay: 99% Specification: CP, EP, In-house, as required Molecular Formula: C21H25ClO6 Molecular Weight: 408.88 Shelf Life: 2 Years Package: 25kg/drum
